Cover Image
市場調查報告書

慢性腎臟病造成的貧血:流行病學、病患人數的市場預測、治療流程、已上市及開發中的藥物分析

Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035

出版商 Datamonitor Healthcare 商品編碼 365170
出版日期 內容資訊 英文 324 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
慢性腎臟病造成的貧血:流行病學、病患人數的市場預測、治療流程、已上市及開發中的藥物分析 Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035
出版日期: 2018年01月11日 內容資訊: 英文 324 Pages
簡介

由於新的HIF抑制劑Roxadustat的投入抵消生技仿製藥的Epogen的侵蝕,推動市場成長。

本報告提供慢性腎臟病的貧血治療藥趨勢調查,市場定義和概要,疾病定義與診斷,目前治療選擇,處方趨勢,未滿足需求,主要的已上市產品簡介,開發平台趨勢等彙整資料。

預測:慢性腎臟病造成的貧血

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • Aranesp (darbepoetin alfa)
  • Auryxia (ferric citrate)
  • DexFerrum (iron dextran)
  • Epogen (epoetin alfa)
  • Feraccru (ferric trimaltol)
  • Feraheme (ferumoxytol)
  • Injectafer (ferric carboxymaltose)
  • Mircera (methoxy polyethylene glycol-epoetin beta)
  • NeoRecormon (epoetin beta)
  • Roxadustat
  • Venofer (iron sucrose)
  • 主要調查技術

由於治療:慢性腎臟病的貧血

  • 摘要整理
  • 主要調查技術
  • 疾病定義與診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求
  • 未來的治療方法

流行病學:慢性腎臟病造成的貧血

  • 摘要整理
  • 資訊來源、調查手法
  • 預測
  • 流行病學者分析
  • 優勢、規定

已上市藥物:慢性腎臟病造成的貧血

  • 摘要整理
  • 產品概要
  • 產品簡介:Aranesp
  • 產品簡介:Epogen
  • 產品簡介:Mircera
  • 產品簡介:Triferic
  • 產品簡介:Venofer

開發平台:慢性腎臟病造成的貧血

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (開發後期):Auryxia
  • 產品簡介 (開發後期):Feraccru
  • 產品簡介 (開發後期):roxadustat

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13144

Disease Overview

Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.

Market Snapshot

The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.

Physicians expect to switch a significant portion of patients on stable erythropoiesis-stimulating agent (ESA) therapy to oral ESAs within three years of their launch.

Between 2015 and 2035, the number of prevalent cases of anemia in chronic kidney disease (CKD) is forecasted to increase from 11.3 million to 14.9 million. This is due to a forecasted increase in the number of prevalent CKD cases, which is driven by population growth and aging, although increasing diabetes prevalence will also play a major role in shaping the future prevalence of anemia in CKD.

Use of erythropoiesis-stimulating agents, the standard of care for anemia in CKD, may decline due to cost and safety concerns.

Pipeline therapies plan to capture market share by reducing costs and safety concerns associated with treatment.

Table of Contents

12 FORECAST: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

12 EXECUTIVE SUMMARY

13 RECENT FORECAST UPDATES

14 MARKET DYNAMICS

21 FORECAST AND FUTURE TRENDS

29 MARKET DEFINITION AND METHODOLOGY

34 PRIMARY RESEARCH METHODOLOGY

36 PRODUCT PROFILE: ARANESP

52 PRODUCT PROFILE: AURYXIA

62 PRODUCT PROFILE: DEXFERRUM

66 PRODUCT PROFILE: EPOGEN

79 PRODUCT PROFILE (LATE STAGE): FERACCRU

90 PRODUCT PROFILE: FERAHEME

94 PRODUCT PROFILE: INJECTAFER

104 PRODUCT PROFILE: MIRCERA

120 PRODUCT PROFILE: NEORECORMON

124 PRODUCT PROFILE: VENOFER

137 PRODUCT PROFILE (LATE STAGE): ROXADUSTAT

151 TREATMENT: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 09 March 2016)

151 EXECUTIVE SUMMARY

152 PRIMARY RESEARCH METHODOLOGY

154 DISEASE DEFINITION AND DIAGNOSIS

157 PATIENT SEGMENTATION

159 COUNTRY TREATMENT TREES

160 CURRENT TREATMENT OPTIONS

163 PRESCRIBING TRENDS

174 UNMET NEEDS IN ANEMIA IN CHRONIC KIDNEY DISEASE

175 FUTURE TREATMENT

180 EPIDEMIOLOGY: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 20 April 2016)

180 EXECUTIVE SUMMARY

182 SOURCES AND METHODOLOGY

192 FORECAST

200 EPIDEMIOLOGIST INSIGHT

202 STRENGTHS AND LIMITATIONS

205 MARKETED DRUGS: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

205 EXECUTIVE SUMMARY

206 PRODUCT OVERVIEW

207 PRODUCT PROFILE: ARANESP

223 PRODUCT PROFILE: AURYXIA

233 PRODUCT PROFILE: DEXFERRUM

237 PRODUCT PROFILE: EPOGEN

250 PRODUCT PROFILE: FERAHEME

254 PRODUCT PROFILE: INJECTAFER

264 PRODUCT PROFILE: MIRCERA

280 PRODUCT PROFILE: NEORECORMON

284 PRODUCT PROFILE: VENOFER

297 PIPELINE: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

297 EXECUTIVE SUMMARY

298 CLINICAL PIPELINE OVERVIEW

299 PRODUCT PROFILE (LATE STAGE): FERACCRU

310 PRODUCT PROFILE (LATE STAGE): ROXADUSTAT

LIST OF FIGURES

  • 14 Figure 1: Anemia in chronic kidney disease - current and future market dynamics analysis
  • 15 Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for anemia in chronic kidney disease
  • 22 Figure 3: Anemia in chronic kidney disease market sales across the US, Japan, and five major EU markets, by country, 2015-24
  • 23 Figure 4: Sales of ESAs and roxadustat in the US, Japan, and five major EU markets, by drug, 2015-24
  • 24 Figure 5: Anemia in chronic kidney disease market sales in the US, Japan, and five major EU markets, by class, 2015-24
  • 25 Figure 6: Sales of Epogen and biosimilar epoetin alfa in the US, Japan, and five major EU markets, by drug, 2015-24
  • 26 Figure 7: Sales of biosimilar epoetin alfa in the US, Japan, and five major EU markets, by country, 2015-24
  • 27 Figure 8: Sales of iron supplements in anemia in chronic kidney disease in the US, Japan, and five major EU markets, by drug, 2015-24
  • 30 Figure 9: Patient-based forecast methodology for anemia in chronic kidney disease
  • 32 Figure 10: Price sources and calculations, by country
  • 44 Figure 11: Aranesp for anemia in chronic kidney disease - SWOT analysis
  • 45 Figure 12: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • 46 Figure 13: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • 48 Figure 14: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 55 Figure 15: Auryxia for anemia in chronic kidney disease - SWOT analysis
  • 56 Figure 16: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • 57 Figure 17: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • 59 Figure 18: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 63 Figure 19: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015-24
  • 72 Figure 20: Epogen for anemia in chronic kidney disease - SWOT analysis
  • 73 Figure 21: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • 74 Figure 22: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • 76 Figure 23: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • 82 Figure 24: Feraccru for anemia in chronic kidney disease - SWOT analysis
  • 83 Figure 25: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • 84 Figure 26: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • 86 Figure 27: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 91 Figure 28: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • 97 Figure 29: Injectafer for anemia in chronic kidney disease - SWOT analysis
  • 98 Figure 30: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • 99 Figure 31: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • 101 Figure 32: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015-24
  • 112 Figure 33: Mircera for anemia in chronic kidney disease - SWOT analysis
  • 113 Figure 34: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • 114 Figure 35: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • 116 Figure 36: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 121 Figure 37: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24
  • 129 Figure 38: Venofer for anemia in chronic kidney disease - SWOT analysis
  • 130 Figure 39: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • 131 Figure 40: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • 133 Figure 41: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 143 Figure 42: Roxadustat for anemia in chronic kidney disease - SWOT analysis
  • 144 Figure 43: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • 145 Figure 44: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • 147 Figure 45: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 156 Figure 46: Physician-estimated rate of diagnosis of anemia in chronic kidney disease, by country (%)
  • 157 Figure 47: Proportion of anemia in chronic kidney disease patients at each grade of disease, by country (%)
  • 158 Figure 48: Proportion of patients with anemia in chronic kidney disease receiving treatment from each physician type, by country (%)
  • 164 Figure 49: Proportion of patients with mild anemia receiving each treatment type, by country (%)
  • 165 Figure 50: Proportion of patients with moderate anemia receiving each treatment type, by country (%)
  • 166 Figure 51: Proportion of patients with severe anemia receiving each treatment type, by country (%)
  • 167 Figure 52: Proportion of patients with very severe anemia receiving each treatment type, by country (%)
  • 169 Figure 53: Proportion of patients prescribed top five pharmacological treatments, by country (%)
  • 170 Figure 54: Percentage of anemia in chronic kidney disease patients on pharmacological treatment receiving each ESA (alone or in combination), by country
  • 171 Figure 55: Percentage of anemia in chronic kidney disease patients on pharmacological treatment receiving each iron supplement (alone or in combination), by country
  • 172 Figure 56: Average length of iron supplement treatment, by anemia grade (days)
  • 175 Figure 57: Expected epoetin alfa biosimilar use in new patients compared to physician-reported use in the 5EU and Japan, by country (%)
  • 176 Figure 58: Expected epoetin alfa biosimilar use in patients currently receiving epoetin alfa compared to physician-reported use in the 5EU and Japan, by country (%)
  • 177 Figure 59: Newly diagnosed patients expected to be prescribed an oral ESA, one and three years post-launch, by country (%)
  • 178 Figure 60: Patients on stable ESA therapy expected to be switched to an oral ESA, one and three years post-launch, by country (%)
  • 195 Figure 61: Trend in prevalent cases of anemia in chronic kidney disease in the US, Japan, and five major EU markets, by country, 2015-35
  • 196 Figure 62: Absolute growth of prevalent cases of anemia in chronic kidney disease in the US, Japan, and five major EU markets, by country, 2015-35
  • 215 Figure 63: Aranesp for anemia in chronic kidney disease - SWOT analysis
  • 216 Figure 64: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • 217 Figure 65: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • 219 Figure 66: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 226 Figure 67: Auryxia for anemia in chronic kidney disease - SWOT analysis
  • 227 Figure 68: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • 228 Figure 69: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • 230 Figure 70: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 234 Figure 71: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015-24
  • 243 Figure 72: Epogen for anemia in chronic kidney disease - SWOT analysis
  • 244 Figure 73: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • 245 Figure 74: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • 247 Figure 75: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • 251 Figure 76: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • 257 Figure 77: Injectafer for anemia in chronic kidney disease - SWOT analysis
  • 258 Figure 78: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • 259 Figure 79: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • 261 Figure 80: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015-24
  • 272 Figure 81: Mircera for anemia in chronic kidney disease - SWOT analysis
  • 273 Figure 82: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • 274 Figure 83: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • 276 Figure 84: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 281 Figure 85: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24
  • 289 Figure 86: Venofer for anemia in chronic kidney disease - SWOT analysis
  • 290 Figure 87: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • 291 Figure 88: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • 293 Figure 89: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 302 Figure 90: Feraccru for anemia in chronic kidney disease - SWOT analysis
  • 303 Figure 91: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • 304 Figure 92: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • 306 Figure 93: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • 316 Figure 94: Roxadustat for anemia in chronic kidney disease - SWOT analysis
  • 317 Figure 95: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • 318 Figure 96: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • 320 Figure 97: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24

LIST OF TABLES

  • 29 Table 1: Summary of drug classes and molecules included in Datamonitor Healthcare's anemia in chronic kidney disease patient-based forecast
  • 33 Table 2: Exchange rates used for calculating prices
  • 34 Table 3: Hematologists and nephrologists surveyed for the anemia in chronic kidney disease primary research study, 2015
  • 36 Table 4: Aranesp drug profile
  • 38 Table 5: Aranesp pivotal trial data in anemia in chronic kidney disease
  • 41 Table 6: Aranesp other late-phase trial data in anemia in chronic kidney disease
  • 49 Table 7: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 53 Table 8: Auryxia drug profile
  • 54 Table 9: Auryxia Phase III data in anemia in chronic kidney disease
  • 54 Table 10: Auryxia Phase II data in anemia in chronic kidney disease
  • 60 Table 11: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 64 Table 12: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country ($m), 2015-24
  • 66 Table 13: Epogen drug profile
  • 68 Table 14: Epogen pivotal trial data in anemia in chronic kidney disease
  • 71 Table 15: Epogen other late-phase trial data in anemia in chronic kidney disease
  • 77 Table 16: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • 80 Table 17: Feraccru drug profile
  • 81 Table 18: Feraccru Phase III trials in anemia in chronic kidney disease
  • 87 Table 19: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 92 Table 20: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • 95 Table 21: Injectafer drug profile
  • 96 Table 22: Injectafer Phase III data in anemia in chronic kidney disease
  • 102 Table 23: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015-24
  • 104 Table 24: Mircera drug profile
  • 106 Table 25: Mircera pivotal trial data in anemia in chronic kidney disease
  • 111 Table 26: Mircera late-phase trial data in anemia in chronic kidney disease
  • 117 Table 27: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 122 Table 28: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24
  • 125 Table 29: Venofer drug profile
  • 126 Table 30: Venofer pivotal trial data in anemia in chronic kidney disease
  • 128 Table 31: Venofer late-phase trial data in anemia in chronic kidney disease
  • 134 Table 32: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 138 Table 33: Roxadustat drug profile
  • 139 Table 34: Roxadustat Phase III trials in anemia in chronic kidney disease
  • 141 Table 35: Roxadustat Phase II and III data in anemia in chronic kidney disease
  • 148 Table 36: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 152 Table 37: Nephrologists and hematologists surveyed for the anemia in chronic kidney disease primary research study, November 2015
  • 155 Table 38: Grades of anemia in chronic kidney disease and corresponding hemoglobin levels
  • 161 Table 39: Treatments available for anemia in chronic kidney disease across the US, Japan, and five major EU markets
  • 182 Table 40: Stages of chronic kidney disease
  • 183 Table 41: Definitions of anemia
  • 184 Table 42: Sources used for anemia in CKD patients analysis in the US, Japan, and five major EU markets
  • 185 Table 43: Notable sources not used for anemia in CKD patients analysis in the US, Japan, and five major EU markets
  • 193 Table 44: Prevalent cases of anemia in chronic kidney disease in the US, Japan, and five major EU markets, by country, 2015-35
  • 197 Table 45: Gender-specific prevalent cases of anemia in chronic kidney disease in the US, Japan, and five major EU markets, by country, 2015
  • 198 Table 46: Stage-specific prevalent cases of anemia in chronic kidney disease, by country, 2015
  • 206 Table 47: Key marketed drugs for anemia in chronic kidney disease
  • 207 Table 48: Aranesp drug profile
  • 209 Table 49: Aranesp pivotal trial data in anemia in chronic kidney disease
  • 212 Table 50: Aranesp other late-phase trial data in anemia in chronic kidney disease
  • 220 Table 51: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 224 Table 52: Auryxia drug profile
  • 225 Table 53: Auryxia Phase III data in anemia in chronic kidney disease
  • 225 Table 54: Auryxia Phase II data in anemia in chronic kidney disease
  • 231 Table 55: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 235 Table 56: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country ($m), 2015-24
  • 237 Table 57: Epogen drug profile
  • 239 Table 58: Epogen pivotal trial data in anemia in chronic kidney disease
  • 242 Table 59: Epogen other late-phase trial data in anemia in chronic kidney disease
  • 248 Table 60: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • 252 Table 61: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • 255 Table 62: Injectafer drug profile
  • 256 Table 63: Injectafer Phase III data in anemia in chronic kidney disease
  • 262 Table 64: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015-24
  • 264 Table 65: Mircera drug profile
  • 266 Table 66: Mircera pivotal trial data in anemia in chronic kidney disease
  • 271 Table 67: Mircera late-phase trial data in anemia in chronic kidney disease
  • 277 Table 68: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 282 Table 69: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24
  • 285 Table 70: Venofer drug profile
  • 286 Table 71: Venofer pivotal trial data in anemia in chronic kidney disease
  • 288 Table 72: Venofer late-phase trial data in anemia in chronic kidney disease
  • 294 Table 73: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 298 Table 74: Phase III pipeline products in development for anemia in chronic kidney disease
  • 300 Table 75: Feraccru drug profile
  • 301 Table 76: Feraccru Phase III trials in anemia in chronic kidney disease
  • 307 Table 77: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 311 Table 78: Roxadustat drug profile
  • 312 Table 79: Roxadustat Phase III trials in anemia in chronic kidney disease
  • 314 Table 80: Roxadustat Phase II and III data in anemia in chronic kidney disease
  • 321 Table 81: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Back to Top